Option Care Health, Inc. (OPCH)
NEUTRALFondamental
72
Prix
$23.36
Capitalisation boursière
$3.58B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$5.67B
12 derniers mois (au 31/03/2026)
Résultat net
$206M
12 derniers mois (au 31/03/2026)
Flux de trésorerie libre
$217M
Capitaux propres totaux
$1.33B
Passif total
$2.13B
Ratio de liquidité général
1.64
Couverture des intérêts
6.06
Dette/EBITDA
3.13
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$30.30
Prix actuel
$23.36
Marge de sécurité
+22.9%
Fourchette de juste valeur
$19.70 - $40.91
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
18.49
ROE
15.7%
Ratio P/B
2.75
P/FCF
17.49
Marge brute
19.2%
ROIC
9.9%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
9.9%
WACC
6.8%
ROIC − WACC
+3.1 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (20)
- EPS shows upward trend
- EPS CAGR 15.84%
- Price CAGR 19.01%
- ROIC 9.9%
- P/FCF 17.49
- P/B Ratio 2.75
- Debt/Equity ratio
- Operating Margin 5.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.8%
- Revenue Growth 5Y 13.3%
- Analyst Consensus 68% Buy
- Earnings Quality (OCF/NI) 1.23
- Share Dilution -5.1%
- Piotroski F-Score 5/9
Échoué (6)
- Gross Margin 19.2%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 2.4%
- Net Margin Trend 3.6% vs 4.1%
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. John Charles Rademacher | CEO, President & Director | 58 |
| Mr. Luke Whitworth | Chief Operating Officer | 44 |
| Mr. Collin G. Smyser | General Counsel & Corporate Secretary | 46 |
| Ms. Nicole Maggio | Senior VP, Controller & Principal Accounting Officer | 42 |
| Mr. Brett Michalak | Chief Technology Officer | - |
| Ms. Alyssa Moy | Chief Information Officer | - |
| Ms. Stacey Mahone | Senior VP & Chief Compliance Officer | - |
| Mr. Jorge Ramirez | Senior VP of Strategy and Corporate Development | - |
| Mr. Michael Bavaro | Chief Human Resources & Chief Diversity Officer | 47 |
| Ms. Julie Koenig | Senior Vice President of Operations | - |
Risque d'audit
1
Risque du conseil
2
Risque de rémunération
4
Risque droits des actionnaires
5
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for OPCH, sourced from Markets Gazette.
- 2/24/2026NEUTRALOption Care (OPCH) Earnings Call Transcript
Investors in Option Care Health (OPCH) are awaiting the release of the earnings call transcript, scheduled for February 24, 2026. While the specific content is not yet available, this event is crucial for understanding the company's financial performance and future outlook. Earnings calls provide detailed insights into revenues, profits, margins, and guidance, which are fundamental elements for assessing a company's operational and strategic health. The analysis of this data will enable analysts and shareholders to make informed judgments about the stock's short- to medium-term trajectory. The current lack of content implies a waiting period for the market, which will react once the information is made public.
via Markets Gazette